Tenelia (teneligliptin; Mitsubishi Tanabe) is a member of the dipeptidyl peptidase-IV (DPP-IV) inhibitor class. DPP-IV is an enzyme responsible for the rapid degradation of the incretin hormone glucagon-like peptide-1 (GLP-1), which is released postprandially from the gut. Inhibition of DPP-IV augments the amount of active GLP-1, which in turn triggers increased insulin secretion from the pancreas in a glucose-dependent manner and suppresses the release of glucagon, resulting in lowered blood glucose levels. Generic alogliptin was approved by the US Food and Drug Administration in April 2016.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Tenelia : Diabetes type 2
LIST OF FIGURES
5 Figure 1: Tenelia sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016–25
6 Table 1: Tenelia sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016–25
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.